533 related articles for article (PubMed ID: 31209265)
1. Phenotype plasticity as enabler of melanoma progression and therapy resistance.
Arozarena I; Wellbrock C
Nat Rev Cancer; 2019 Jul; 19(7):377-391. PubMed ID: 31209265
[TBL] [Abstract][Full Text] [Related]
2. Cooperative behaviour and phenotype plasticity evolve during melanoma progression.
Rowling EJ; Miskolczi Z; Nagaraju R; Wilcock DJ; Wang P; Telfer B; Li Y; Lasheras-Otero I; Redondo-Muñoz M; Sharrocks AD; Arozarena I; Wellbrock C
Pigment Cell Melanoma Res; 2020 Sep; 33(5):695-708. PubMed ID: 32145051
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression.
Pessoa DO; Rius FE; Papaiz DD; Ayub ALP; Morais AS; de Souza CF; da Paixão VF; Setubal JC; Newton-Bishop J; Nsengimana J; Azevedo H; Reis EM; Jasiulionis MG
Neoplasia; 2021 Apr; 23(4):439-455. PubMed ID: 33845354
[TBL] [Abstract][Full Text] [Related]
4. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
[TBL] [Abstract][Full Text] [Related]
6. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
7. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
8. Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis.
Azevedo H; Pessoa GC; de Luna Vitorino FN; Nsengimana J; Newton-Bishop J; Reis EM; da Cunha JPC; Jasiulionis MG
Clin Epigenetics; 2020 Aug; 12(1):127. PubMed ID: 32831131
[TBL] [Abstract][Full Text] [Related]
9. The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma.
Zhou W; Xu X; Cen Y; Chen J
Front Immunol; 2022; 13():1085766. PubMed ID: 36601121
[TBL] [Abstract][Full Text] [Related]
10. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V; Boivin F; Dalle S; Caramel J
Front Immunol; 2022; 13():873116. PubMed ID: 35432344
[TBL] [Abstract][Full Text] [Related]
11. Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.
Granados K; Poelchen J; Novak D; Utikal J
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167306
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma.
Jayachandran A; Anaka M; Prithviraj P; Hudson C; McKeown SJ; Lo PH; Vella LJ; Goding CR; Cebon J; Behren A
Oncotarget; 2014 Jul; 5(14):5782-97. PubMed ID: 25051363
[TBL] [Abstract][Full Text] [Related]
13. Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment.
Seip K; Jørgensen K; Haselager MV; Albrecht M; Haugen MH; Egeland EV; Lucarelli P; Engebraaten O; Sauter T; Mælandsmo GM; Prasmickaite L
Cancer Lett; 2018 Dec; 439():1-13. PubMed ID: 30240588
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.
Thakur R; Laye JP; Lauss M; Diaz JMS; O'Shea SJ; Poźniak J; Filia A; Harland M; Gascoyne J; Randerson-Moor JA; Chan M; Mell T; Jönsson G; Bishop DT; Newton-Bishop J; Barrett JH; Nsengimana J
Clin Cancer Res; 2019 Dec; 25(24):7424-7435. PubMed ID: 31515461
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal-like transition events in melanoma.
Pedri D; Karras P; Landeloos E; Marine JC; Rambow F
FEBS J; 2022 Mar; 289(5):1352-1368. PubMed ID: 33999497
[TBL] [Abstract][Full Text] [Related]
16. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
Kong X; Kuilman T; Shahrabi A; Boshuizen J; Kemper K; Song JY; Niessen HWM; Rozeman EA; Geukes Foppen MH; Blank CU; Peeper DS
Nature; 2017 Oct; 550(7675):270-274. PubMed ID: 28976960
[TBL] [Abstract][Full Text] [Related]
17. Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity.
Jain P; Pillai M; Duddu AS; Somarelli JA; Goyal Y; Jolly MK
Semin Cancer Biol; 2023 Nov; 96():48-63. PubMed ID: 37788736
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
[TBL] [Abstract][Full Text] [Related]
19. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
20. Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.
Massi D; Mihic-Probst D; Schadendorf D; Dummer R; Mandalà M
Cancer Treat Rev; 2020 Aug; 88():102060. PubMed ID: 32619863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
